716C>T, p.T239M) genotype and P-PTH concentration and U-Pi/U-Crea in healthy school children. In addition, we found an association between FGF23 diplotype and total Afatinib hip BMD Z-scores, but not with other skeletal parameters. We observed a genetic variant that influences circulating PTH and phosphate without

affecting serum FGF23 concentration. Future studies are needed to confirm our findings in a larger cohort and to elucidate the impact of other genes implicated in phosphate homeostasis [27] on bone density parameters and cardiovascular morbidity as to better clarify the link between gene polymorphisms and diseases secondary to variations in phosphate regulation. Lamberg-Allardt has received payment for lectures from Roche and Nutricia in Finland. Other authors have no conflicts of interest to report. We are grateful to the children and adolescents who took part in this research. We thank

Nea Boman, Heini Karp and Elisa Saarnio for technical assistance. This work was supported by the Foundation for Pediatric Research, the Yrjö Jahnsson Foundation, the Ministry of Education, the Academy of Finland, the Helsinki University Central Hospital research funds, the Sigrid Juselius Foundation and the Folkhälsan Research Foundation; all Helsinki, Finland. “
“The nature of the relationship between bone mineral density (BMD) and osteoarthritis (OA) remains a topic

of debate [1]. While epidemiological studies have consistently demonstrated an association between higher BMD and both prevalent [2], [3], [4] and [5] Epigenetic inhibitors library and incident [6], [7] and [8] radiographic OA of the large joints, the mechanisms behind these associations remain unclear; understanding these mechanisms will be key to translating research findings into therapeutic benefit [1]. To address this question from a novel perspective, we set out to investigate the prevalence and phenotype of OA in our cohort of high bone mass (HBM) individuals [9], compared with a control group. HBM individuals many have extreme elevations in BMD likely to be genetically determined [9] and [10] and thus present from early adulthood, constituting a unique population for the investigation of causal pathways between BMD and OA. We have recently shown that HBM is associated with both an increased prevalence of self-reported joint replacement [11], and an increased prevalence of radiographic hip OA with a predominance of bone-forming features (osteophytosis and subchondral sclerosis) [12]. HBM is also associated with other characteristics which may potentially contribute to a higher risk of OA, including increased body mass index (BMI) [13]. While hip and knee OA both increase with age [14], evidence suggests that OA at these two joint sites has different determinants [15].